Communiqué from the Extraordinary Shareholders’ Meeting of Oncology Venture Sweden AB (publ)

Today, January 17, 2017, Oncology Venture Sweden AB (publ) held an Extraordinary Shareholders’ Meeting. A summary of the resolutions follows below. All resolutions were passed with the required majority.

Further information regarding the transactions approved by the Extraordinary Shareholders’ Meeting can be found in the company’s press release on December 30, 2016, and in the complete proposals for the Extraordinary Shareholders’ Meeting.

Approval of (i) transfer of shares in 2X Oncology, Inc. to Medical Prognosis Institute A/S and (ii) directed new issue in 2X Oncology, Inc.

The Extraordinary Shareholders’ Meeting resolved, in accordance with the proposal from the board of directors, to approve (i) that Oncology Venture ApS transfers shares in 2X Oncology, Inc. to Medical Prognosis Institute A/S; and (ii) that existing shareholders in Oncology Venture Sweden AB participate in the seed round in 2X Oncology, Inc.

Approval of (i) transfer of shares in OV-SPV2 ApS to Medical Prognosis Institute A/S and (ii) directed new issue in OV-SPV2 ApS

The Extraordinary Shareholders’ Meeting resolved, in accordance with the proposal from the board of directors, to approve (i) that Medical Prognosis Institute A/S receives shares in OV-SPV2 ApS; and (ii) that Sass & Larsen ApS, which is an existing shareholder in Oncology Venture Sweden AB participates in the seed round in OV-SPV2 ApS.

Approval of agreement with Medical Prognosis Institute A/S regarding extended exclusivity and resolution on issue of warrants to Medical Prognosis Institute A/S

The Extraordinary Shareholders’ Meeting resolved, in accordance with the proposal from the board of directors, to approve that Oncology Venture ApS acquires extended license rights from Medical Prognosis Institute A/S and that Oncology Venture Sweden AB shall issue 302,243 warrants to Medical Prognosis Institute A/S.

Malmö on 17 January, 2017

Oncology Venture Sweden AB (publ)

THE BOARD OF DIRECTORS

For further information, please contact

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 17th 2017.

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.